2023-10-032024-10-312024-10-31falseSC784782MR PHARM 741 LIMITED2025-05-09falseiso4217:GBPxbrli:pureSC7847822023-10-03SC7847822024-10-31SC7847822023-10-032024-10-31SC7847822023-10-02SC7847822023-10-02SC7847822023-10-022023-10-02SC784782bus:SmallEntities2023-10-032024-10-31SC784782bus:AuditExempt-NoAccountantsReport2023-10-032024-10-31SC784782bus:FullAccounts2023-10-032024-10-31SC784782bus:PrivateLimitedCompanyLtd2023-10-032024-10-31SC784782core:WithinOneYear2024-10-31SC784782core:AfterOneYear2024-10-31SC784782core:WithinOneYear2023-10-02SC784782core:AfterOneYear2023-10-02SC784782core:ShareCapital2024-10-31SC784782core:SharePremium2024-10-31SC784782core:RevaluationReserve2024-10-31SC784782core:OtherReservesSubtotal2024-10-31SC784782core:RetainedEarningsAccumulatedLosses2024-10-31SC784782core:ShareCapital2023-10-02SC784782core:SharePremium2023-10-02SC784782core:RevaluationReserve2023-10-02SC784782core:OtherReservesSubtotal2023-10-02SC784782core:RetainedEarningsAccumulatedLosses2023-10-02SC784782core:LandBuildings2024-10-31SC784782core:PlantMachinery2024-10-31SC784782core:Vehicles2024-10-31SC784782core:FurnitureFittings2024-10-31SC784782core:OfficeEquipment2024-10-31SC784782core:NetGoodwill2024-10-31SC784782core:IntangibleAssetsOtherThanGoodwill2024-10-31SC784782core:ListedExchangeTraded2024-10-31SC784782core:UnlistedNon-exchangeTraded2024-10-31SC784782core:LandBuildings2023-10-02SC784782core:PlantMachinery2023-10-02SC784782core:Vehicles2023-10-02SC784782core:FurnitureFittings2023-10-02SC784782core:OfficeEquipment2023-10-02SC784782core:NetGoodwill2023-10-02SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-02SC784782core:ListedExchangeTraded2023-10-02SC784782core:UnlistedNon-exchangeTraded2023-10-02SC784782core:LandBuildings2023-10-032024-10-31SC784782core:PlantMachinery2023-10-032024-10-31SC784782core:Vehicles2023-10-032024-10-31SC784782core:FurnitureFittings2023-10-032024-10-31SC784782core:OfficeEquipment2023-10-032024-10-31SC784782core:NetGoodwill2023-10-032024-10-31SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-032024-10-31SC784782core:ListedExchangeTraded2023-10-032024-10-31SC784782core:UnlistedNon-exchangeTraded2023-10-032024-10-31SC784782core:MoreThanFiveYears2023-10-032024-10-31SC784782core:Non-currentFinancialInstruments2024-10-31SC784782core:Non-currentFinancialInstruments2023-10-02SC784782dpl:CostSales2023-10-032024-10-31SC784782dpl:DistributionCosts2023-10-032024-10-31SC784782core:LandBuildings2023-10-032024-10-31SC784782core:PlantMachinery2023-10-032024-10-31SC784782core:Vehicles2023-10-032024-10-31SC784782core:FurnitureFittings2023-10-032024-10-31SC784782core:OfficeEquipment2023-10-032024-10-31SC784782dpl:AdministrativeExpenses2023-10-032024-10-31SC784782core:NetGoodwill2023-10-032024-10-31SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-032024-10-31SC784782dpl:GroupUndertakings2023-10-032024-10-31SC784782dpl:ParticipatingInterests2023-10-032024-10-31SC784782dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-032024-10-31SC784782core:ListedExchangeTraded2023-10-032024-10-31SC784782dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-032024-10-31SC784782core:UnlistedNon-exchangeTraded2023-10-032024-10-31SC784782dpl:CostSales2023-10-022023-10-02SC784782dpl:DistributionCosts2023-10-022023-10-02SC784782core:LandBuildings2023-10-022023-10-02SC784782core:PlantMachinery2023-10-022023-10-02SC784782core:Vehicles2023-10-022023-10-02SC784782core:FurnitureFittings2023-10-022023-10-02SC784782core:OfficeEquipment2023-10-022023-10-02SC784782dpl:AdministrativeExpenses2023-10-022023-10-02SC784782core:NetGoodwill2023-10-022023-10-02SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-022023-10-02SC784782dpl:GroupUndertakings2023-10-022023-10-02SC784782dpl:ParticipatingInterests2023-10-022023-10-02SC784782dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-022023-10-02SC784782core:ListedExchangeTraded2023-10-022023-10-02SC784782dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-022023-10-02SC784782core:UnlistedNon-exchangeTraded2023-10-022023-10-02SC784782core:NetGoodwill2024-10-31SC784782core:IntangibleAssetsOtherThanGoodwill2024-10-31SC784782core:LandBuildings2024-10-31SC784782core:PlantMachinery2024-10-31SC784782core:Vehicles2024-10-31SC784782core:FurnitureFittings2024-10-31SC784782core:OfficeEquipment2024-10-31SC784782core:AfterOneYear2024-10-31SC784782core:WithinOneYear2024-10-31SC784782core:ListedExchangeTraded2024-10-31SC784782core:UnlistedNon-exchangeTraded2024-10-31SC784782core:ShareCapital2024-10-31SC784782core:SharePremium2024-10-31SC784782core:RevaluationReserve2024-10-31SC784782core:OtherReservesSubtotal2024-10-31SC784782core:RetainedEarningsAccumulatedLosses2024-10-31SC784782core:NetGoodwill2023-10-02SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-02SC784782core:LandBuildings2023-10-02SC784782core:PlantMachinery2023-10-02SC784782core:Vehicles2023-10-02SC784782core:FurnitureFittings2023-10-02SC784782core:OfficeEquipment2023-10-02SC784782core:AfterOneYear2023-10-02SC784782core:WithinOneYear2023-10-02SC784782core:ListedExchangeTraded2023-10-02SC784782core:UnlistedNon-exchangeTraded2023-10-02SC784782core:ShareCapital2023-10-02SC784782core:SharePremium2023-10-02SC784782core:RevaluationReserve2023-10-02SC784782core:OtherReservesSubtotal2023-10-02SC784782core:RetainedEarningsAccumulatedLosses2023-10-02SC784782core:NetGoodwill2023-10-02SC784782core:IntangibleAssetsOtherThanGoodwill2023-10-02SC784782core:LandBuildings2023-10-02SC784782core:PlantMachinery2023-10-02SC784782core:Vehicles2023-10-02SC784782core:FurnitureFittings2023-10-02SC784782core:OfficeEquipment2023-10-02SC784782core:AfterOneYear2023-10-02SC784782core:WithinOneYear2023-10-02SC784782core:ListedExchangeTraded2023-10-02SC784782core:UnlistedNon-exchangeTraded2023-10-02SC784782core:ShareCapital2023-10-02SC784782core:SharePremium2023-10-02SC784782core:RevaluationReserve2023-10-02SC784782core:OtherReservesSubtotal2023-10-02SC784782core:RetainedEarningsAccumulatedLosses2023-10-02SC784782core:AfterOneYear2023-10-032024-10-31SC784782core:WithinOneYear2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:CostValuation2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-10-032024-10-31SC784782core:Non-currentFinancialInstrumentscore:CostValuation2024-10-31SC784782core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-31SC784782core:Non-currentFinancialInstrumentscore:CostValuation2023-10-02SC784782core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-10-02SC784782core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-10-02SC784782bus:Director12023-10-032024-10-31

MR PHARM 741 LIMITED

Registered Number
SC784782
(Scotland)

Unaudited Financial Statements for the Period ended
31 October 2024

MR PHARM 741 LIMITED
Company Information
for the period from 3 October 2023 to 31 October 2024

Director

RASUL, Muniba

Registered Address

23 Callum Drive
Dumfries
DG1 3EF

Registered Number

SC784782 (Scotland)
MR PHARM 741 LIMITED
Balance Sheet as at
31 October 2024

Notes

2024

£

£

Fixed assets
Tangible assets3926
926
Current assets
Cash at bank and on hand6,877
6,877
Creditors amounts falling due within one year4(4,597)
Net current assets (liabilities)2,280
Total assets less current liabilities3,206
Net assets3,206
Capital and reserves
Called up share capital100
Profit and loss account3,106
Shareholders' funds3,206
The financial statements were approved and authorised for issue by the Director on 9 May 2025, and are signed on its behalf by:
RASUL, Muniba
Director
Registered Company No. SC784782
MR PHARM 741 LIMITED
Notes to the Financial Statements
for the period ended 31 October 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Office Equipment3
2.Average number of employees

2024
Average number of employees during the year0
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions1,1491,149
At 31 October 241,1491,149
Depreciation and impairment
Charge for year223223
At 31 October 24223223
Net book value
At 31 October 24926926
At 02 October 23--
4.Creditors: amounts due within one year

2024

£
Taxation and social security3,486
Other creditors121
Accrued liabilities and deferred income990
Total4,597
5.Directors advances, credits and guarantees
Included in other creditors is an amount of £121 relates to the directors' loan account.